Haemonetics buys remaining shares in Arryx
This article was originally published in Clinica
Blood separation and processing systems developer Haemonetics has agreed to acquire outright Arryx, a privately-held nanotechnology company in which Haemonetics already has a $5m equity stake. The Braintree, Massachusetts-based firm will pay up to $26m in cash for all remaining shares of Arryx.
You may also be interested in...
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.